### Check for updates

#### **OPEN ACCESS**

APPROVED BY Frontiers Editorial Office, Frontiers Media SA, Switzerland

\*CORRESPONDENCE Guangyao Li ⊠ 425293675@qq.com Min Li ⊠ doctorlimin@gzucm.edu.cn Jia Xiong ⊠ 12366104@qq.com

RECEIVED 07 July 2024 ACCEPTED 15 July 2024 PUBLISHED 01 August 2024

#### CITATION

Huang Y, Tan T, Liu L, Yan Z, Deng Y, Li G, Li M and Xiong J (2024) Corrigendum: Exercise for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. *Front. Neurol.* 15:1460992. doi: 10.3389/fneur.2024.1460992

### COPYRIGHT

© 2024 Huang, Tan, Liu, Yan, Deng, Li, Li and Xiong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Exercise for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials

# Yingjie Huang<sup>1</sup>, Tian Tan<sup>2</sup>, Lu Liu<sup>3</sup>, Zijian Yan<sup>3</sup>, Yuexia Deng<sup>4</sup>, Guangyao Li<sup>5\*</sup>, Min Li<sup>2\*</sup> and Jia Xiong<sup>6\*</sup>

<sup>1</sup>Guangzhou University of Chinese Medicine, Guangzhou, China, <sup>2</sup>Clinical Medical College of Acupuncture Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China, <sup>3</sup>The First Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China, <sup>4</sup>Southern Theater General Hospital, Guangzhou, China, <sup>5</sup>Department of Traditional Chinese Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, <sup>6</sup>Nanchang Hongdu Hospital of Traditional Chinese Medicine, Nanchang, Jiangxi Province, China

## KEYWORDS

exercise therapy, chemotherapy-induced peripheral neuropathy, CIPN, efficacy, metaanalysis

## A corrigendum on

Exercise for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials

by Huang, Y., Tan, T., Liu, L., Yan, Z., Deng, Y., Li, G., Li, M., and Xiong, J. (2024). *Front. Neurol.* 14:1252259. doi: 10.3389/fneur.2023.1252259

In the published article, there was an error in [Figures 3–10 and Table 1] as published. [The figures and table incorrectly list studies with first names of the authors, instead of last names]. The corrected [Figures 3–10 and Table 1] and their captions appear below.

In the published article, there was an error in [Supplementary Figures 1–3]. [The supplementary figures incorrectly list studies with first names of the authors, instead of last names]. The correct material statement published in online.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

### TABLE 1 The basic characteristics of the included studies.

Trail	Country	Sample size (T/C)	Age (y), Mea or median (	an ± SD (Range)	Durat	ion/W	т	с	Main outcomes	Frequency	Follow-up time/week	Cancer	Chemotherapy
			Т	С	Т	С							
Simşek et al. (29)	Turkey	30, 30/30	>18y	>8y	NA	NA	Stretching exercise + balance exercise	Chemotherapy + usual care	12	5 times/ Week	12	Breast cancer	Taxane
Kleckner et al. (25)	USA	170/185	$55.6 \pm 11.8$	$55.9\pm9.7$	$12.1\pm60.9$	$5.7 \pm 10.0$	Strength training	Chemotherapy	13	60 min, qd	6	Breast/ Lymphoma/ Colon/ Lung cancer	Taxane-, platinum-, or vinca alkaloid
Ikio et al. (24)	Japan	19/20	69 (60–89)	64 (57–87)	5 (2–111)	6 (2-93)	Strength training	Chemotherapy	12	30 min, tiw	NA	Hematological malignancy/ Gastrointestin cancer	alkaloids,
Gui et al. (23)	China	51/28	$50 \pm 8$	$52 \pm 7$	12 (23.5)	6 (21.4)	Sensory exercise	Chemotherapy	235	qd	2	Digestive malignancies	Oxaliplatin
Bao et al. (21)	USA	21/20	60.0 (35.5, 77.9)	62.3 (42.4, 79.0)	3.1 (0.5, 10.4)	3.7 (0.9, 15.3)	Yoga	Chemotherapy + usual care	135	60 min, qd	8	Breast/ Uterine/ Ovarian cancer	Taxane-, platinum-, or vinca alkaloid
Dhawan et al. (22)	India	22/23	50.5 ± 7.9	$52.5\pm6.6$	$10.2\pm7.8$	9.8 ± 8.6	Strength training	Chemotherapy	123	30 min, qd	10	Ovarian/ Cervical/ Lung cancer	Paclitaxel, carboplatin


(Continued)

02


TABLE 1 (Continued)


Trait	Country	Sample size (T/C)	Age (y), Mea or median (	an ± SD Range)	Durat	ion/W	т	С	Main outcomes	Frequency	Follow-up time/week	Cancer	Chemotherapy
			Т	С	Т	С							
Müller et al. (27)	Germany	49, 57/57	$51.7 \pm 10.8/53.4 \pm 11.7$	54.5 ± 11.9	$\begin{array}{c} 22.0 \pm 9.3/23.5 \\ \pm 8.9 \end{array}$	23.0 ± 9.4	Sensory exercise/ strength training	Chemotherapy	1	35min, tiw	NA	NA	Taxanes, platinum derivatives, vinca alkaloio
Schwenk et al. (28)	USA	11./11	$68.73\pm8.72$	$71.82\pm8.85$	$49.91 \pm 44.11$	44.63 ± 56.78	Balance exercise	Chemotherapy + health education	4	45 min, biw	4	NA	NA
Vollmers et al. (31)	Germany	17/19	$48.56\pm11.94$	$52.39 \pm 10.14$	12	12	Sensory exercise	Chemotherapy + health education	4	60 min, biw	12	Breast cancer	Taxane
Zimmer et al. (33)	Germany	17/13	68.53 (50–81)	70.00 (50-81)	27.94 ± 24.557	24.38 ± 19.692	Strength training + balance exercise	Chemotherapy + health education	2\$5	60 min, biw	8	Colon cancer	Bevacizumab, regorafenib, trastuzumab
Huang et al. (26)	China	32/34	$54.56\pm9.4$	$57.65 \pm 9.8$	4.66 ± 1.10	4.79 ± 1.06	Aerobic exercise	Chemotherapy + usual care	123	30 min, biw	6	Ovarian cancer	Taxane-, platinum-, or vinca alkaloid
Peng et al. (32)	China	23/23	$53.17\pm9.29$	52.15 ± 7.25	NA	NA	Balance exercise	Chemotherapy + usual care	1235	15–30 min, tiw	12	Breast/ Lymphoma cancer/ Myeloma	Taxanes, platinum, vincristine, bortezomib, thalidomide
Visovsky et al. (30)	USA	19/19	48.8 (24–65)	48.8 (24–65)	NA	NA	Aerobic exercise + strength training	Chemotherapy + health education	124	30 min/ time, 5–7 times/ Week	12	Breast cancer	Taxane
Streckmann et al. (50)	Germany	28/28	44 (20–67)	48 (19–73)	NA	NA	Aerobic exercise + strength training	Chemotherapy	23	biw	36	Lymphoma cancer	Taxanes, platinum, vincristine, bortezomib, thalidomide
Andersen et al. (20)	Canada	22/26	$56.3\pm9.9$	$53 \pm 10.3$	NA	NA	Stretching exercise	Chemotherapy + usual care	1	4 times/ Week	6	Breast cancer	Taxane

T, trial group; C, control group; NA, not reported; ① symptom score (total symptom score, numbness, and tingling); ② quality of life score (total score, physical, functional, social, emotional, and neurotoxicity); ③ pain; ④ balance; ⑤ functional assessment of neurotoxicity (FACT/GOG-NTX); qd, once a day; biw, 2 times/week; tiw, 3 times/week.



Study ID	SMD (95% CI)	% Weight
hands		
Şimşek et al.,2021	-0.11 (-0.62, 0.39)	4.88
Kleckner et al.,2017	-0.29 (-0.50, -0.08)	28.58
Bao et al.,2020	-0.17 (-0.83, 0.48)	2.91
Müller et al.1,2021	0.09 (-0.37, 0.55)	5.80
Müller et al.2,2021	-0.04 (-0.49, 0.41)	6.27
Subtotal (I-squared = 0.0%, p = 0.588)	-0.19 (-0.35, -0.03)	48.45
feet		
Şimşek et al.,2021	-0.18 (-0.68, 0.33)	4.87
Kleckner et al.,2017	-0.17 (-0.38, 0.03)	28.78
Bao et al.,2020	-0.17 (-0.83, 0.48)	2.91
Müller et al.1,2021	-0.20 (-0.66, 0.27)	5.78
Müller et al.2,2021	-0.06 (-0.51, 0.39)	6.27
Peng et al.,2019	-0.63 (-1.29, 0.02)	2.93
Subtotal (I-squared = 0.0%, p = 0.833)	-0.19 (-0.35, -0.03)	51.55
Heterogeneity between groups: p = 0.985		
Overall (I-squared = 0.0%, p = 0.895)	-0.19 (-0.30, -0.08)	100.00
-1.29	0 1.29	





Study ID	SMD (95% CI)	% Weight
Physical !		
Ikio et al.,2021	-0.03 (-0.79, 0.73)	4.25
Zimmer et al. 2018	1.08 (0.30, 1.85)	4.07
Huang et al.,2019	1.59 (1.04, 2.15)	7.93
Subtotal (I-squared = 82.4%, p = 0.003)	1.04 (0.65, 1.43)	16.25
Freedow		
Functional Ikio et al. 2021	0.40 (-0.38, 1.17)	4.18
Dhawan et al. 2020	1.35 (0.70, 2.01)	5.78
Zimmer et al. 2018	0.58 (-0.17, 1.30)	4.51
Subtotal (I-squared = 52.3%, p = 0.123)	0.83 (0.42, 1.25)	14.45
Emotional		
Ikio et al.,2021	0.07 (-0.69, 0.83)	4.25
Gui et al.,2021	-0.12 (-0.58, 0.34)	11.51
Zimmer et al.,2018	-0.14 (-0.86, 0.58)	4.69
Huang et al.,2019 Subtotal (I-squared = 25.3%, p = 0.260)	- 0.51 (0.02, 1.00)	10.17 30.61
Subtotal (I-squared - 25.5%, p - 0.200)	0.11 (-0.17, 0.40)	30.01
Social		
Ikio et al.,2021	-0.08 (-0.82, 0.70)	4.25
Qi et al.,2021	0.00 (-0.46, 0.46)	11.53
Zimmer et al.,2018	-0.23 (-0.96, 0.49)	4.66
Huang et al., 2019 Subtetal (lagraged = 60 5% $p = 0.020$ )	<ul> <li>0.90 (0.40, 1.41)</li> <li>0.91 (0.01, 0.50)</li> </ul>	9.51
Subtotal (I-squared = 69.5%, p = 0.020)	0.24 (-0.04, 0.53)	29.95
Neurotoxity		
Ikio et al.,2021	-0.42 (-1.19, 0.35)	4.15
Zimmer et al.,2018	-0.43 (-1.17, 0.30)	4.58
Subtotal (I-squared = 0.0%, p = 0.97 <del>5)</del>	-0.43 (-0.96, 0.10)	8.74
Heterogeneity between groups: p = 0.000		
Overall (I-squared = 74.3%, p = 0.000)	0.36 (0.20, 0.52)	100.00
-2.15 0	2.15	

FIGURE 7

Forest plot of physical, functional, social, emotional, and neurotoxicity.

